AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 192 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.15 and the average weighting 0.1%.
Links
Filings
- All filings
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Insider transactions
- Shareholder votes
- Significant ownership
- Events
EDGAR links
External links
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,095,406 | -14.3% | 205,875 | -1.9% | 0.00% | 0.0% |
| Q2 2023 | $5,945,669 | +25.2% | 209,946 | +1.6% | 0.00% | 0.0% |
| Q1 2023 | $4,748,220 | -17.8% | 206,714 | +0.5% | 0.00% | 0.0% |
| Q4 2022 | $5,775,128 | -36.4% | 205,667 | -35.9% | 0.00% | -50.0% |
| Q3 2022 | $9,077,000 | +36.2% | 320,959 | +6.8% | 0.00% | 0.0% |
| Q2 2022 | $6,664,000 | -38.0% | 300,549 | -18.5% | 0.00% | 0.0% |
| Q1 2022 | $10,740,000 | -11.5% | 368,918 | -0.1% | 0.00% | 0.0% |
| Q4 2021 | $12,133,000 | -5.9% | 369,145 | +32.1% | 0.00% | -33.3% |
| Q3 2021 | $12,896,000 | -15.8% | 279,447 | +0.6% | 0.00% | 0.0% |
| Q2 2021 | $15,312,000 | +31.7% | 277,844 | +23.4% | 0.00% | +50.0% |
| Q1 2021 | $11,627,000 | +13.5% | 225,163 | -4.7% | 0.00% | 0.0% |
| Q4 2020 | $10,241,000 | +21.3% | 236,358 | -2.0% | 0.00% | 0.0% |
| Q3 2020 | $8,441,000 | -33.2% | 241,176 | +2.0% | 0.00% | -33.3% |
| Q2 2020 | $12,642,000 | +57.7% | 236,406 | +4.6% | 0.00% | 0.0% |
| Q1 2020 | $8,018,000 | -22.8% | 226,011 | +4.0% | 0.00% | 0.0% |
| Q4 2019 | $10,381,000 | +61.7% | 217,410 | +9.7% | 0.00% | +50.0% |
| Q3 2019 | $6,419,000 | -37.6% | 198,104 | -3.9% | 0.00% | -33.3% |
| Q2 2019 | $10,283,000 | -27.8% | 206,144 | -2.5% | 0.00% | -25.0% |
| Q1 2019 | $14,251,000 | +47.1% | 211,331 | +0.6% | 0.00% | +33.3% |
| Q4 2018 | $9,691,000 | -41.6% | 210,171 | -2.4% | 0.00% | -25.0% |
| Q3 2018 | $16,602,000 | -7.3% | 215,292 | +1.2% | 0.00% | -20.0% |
| Q2 2018 | $17,918,000 | +6.1% | 212,733 | +3.0% | 0.01% | 0.0% |
| Q1 2018 | $16,892,000 | +69.8% | 206,564 | +18.7% | 0.01% | +66.7% |
| Q4 2017 | $9,949,000 | -15.5% | 174,029 | -1.3% | 0.00% | 0.0% |
| Q3 2017 | $11,775,000 | +34.8% | 176,405 | +3.9% | 0.00% | +50.0% |
| Q2 2017 | $8,735,000 | +18.0% | 169,773 | +34.0% | 0.00% | 0.0% |
| Q1 2017 | $7,400,000 | +38.5% | 126,715 | -1.0% | 0.00% | 0.0% |
| Q4 2016 | $5,343,000 | -5.3% | 128,006 | +19.8% | 0.00% | 0.0% |
| Q3 2016 | $5,641,000 | +23.6% | 106,824 | -2.0% | 0.00% | +100.0% |
| Q2 2016 | $4,564,000 | +2.2% | 108,966 | -1.0% | 0.00% | 0.0% |
| Q1 2016 | $4,467,000 | -32.5% | 110,045 | +8.0% | 0.00% | -50.0% |
| Q4 2015 | $6,616,000 | -9.1% | 101,904 | -1.1% | 0.00% | 0.0% |
| Q3 2015 | $7,275,000 | -18.1% | 103,057 | +28.9% | 0.00% | 0.0% |
| Q2 2015 | $8,886,000 | +3.7% | 79,947 | -12.0% | 0.00% | 0.0% |
| Q1 2015 | $8,567,000 | -5.6% | 90,847 | +12.1% | 0.00% | 0.0% |
| Q4 2014 | $9,079,000 | +89.2% | 81,037 | +3.6% | 0.00% | +100.0% |
| Q3 2014 | $4,799,000 | -33.0% | 78,227 | -49.9% | 0.00% | 0.0% |
| Q2 2014 | $7,158,000 | +277.3% | 156,222 | +222.3% | 0.00% | 0.0% |
| Q1 2014 | $1,897,000 | +186.6% | 48,468 | +75.3% | 0.00% | – |
| Q4 2013 | $662,000 | -39.5% | 27,655 | -29.2% | 0.00% | – |
| Q3 2013 | $1,094,000 | – | 39,054 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Ventures 2007 General Partner LLC | 1,930,369 | $118,428,000 | 83.56% |
| Third Rock Ventures, LLC | 3,070,090 | $188,350,000 | 21.97% |
| Opaleye Management Inc. | 113,500 | $6,963,225,000 | 5.43% |
| BB BIOTECH AG | 1,890,521 | $115,983,000 | 4.72% |
| Eventide Asset Management | 431,600 | $26,479,000 | 3.70% |
| Atika Capital Management LLC | 54,000 | $3,313,000 | 2.55% |
| Cormorant Asset Management, LP | 100,000 | $6,135,000 | 1.26% |
| BRIDGER MANAGEMENT, LLC | 220,099 | $13,503,000 | 0.92% |
| Ghost Tree Capital, LLC | 20,000 | $1,227,000 | 0.67% |
| HAMILTON LANE ADVISORS LLC | 27,544 | $1,690,000 | 0.55% |